Op2Lysis

About:

Op2Lysis develops drugs for hemorrhagic stroke patients.

Top Investors: European Innovation Council

Description:

Op2Lysis is a neurotic drug developer working on a treatment for hemorrhagic stroke. The company's product is a thrombolytic drug that conveniently dissolves the intracerebral hematoma that occurs after a hemorrhagic stroke, allowing patients to avoid substantial disability and surgery. It was designed to be injected locally via a catheter into the hematoma's core, using micro-invasive surgery.

Total Funding Amount:

2.5M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Boulogne-billancourt, Ile-de-France, France

Founded Date:

2016-01-01

Contact Email:

contact(AT)op2lysis.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2021-10-06

IPO Status:

Private

Industries: